Emergent Biosolutions Inc Stock Price, News & Analysis

Emergent BioSolutions (NYSE:EBS) announced its upcoming participation in two major investor conferences. The company will present at the Wells Fargo 20th Annual Healthcare Conference on September 4, 2025, at 3:00 PM ET, and at the HCW 27th Annual Global Investment Conference on September 9, 2025, at 1:30 PM ET.

Senior management will be available for one-on-one meetings at both events. Investors can access the presentations and replays through the Investors section of Emergent's website.

Emergent BioSolutions (NYSE:EBS) has partnered with Voices for Awareness and Facing Fentanyl Now to support National Fentanyl Prevention and Awareness Day™ on August 21, 2025. The initiative includes high-visibility billboards in Times Square, NYC to raise awareness about fentanyl risks and reduce stigma around opioid poisonings.

The campaign highlights that synthetic opioids like fentanyl contribute to nearly 70% of all overdose deaths. Through its Ready to Rescue initiative, Emergent is focusing on public education and expanding access to naloxone products, including over-the-counter NARCAN® Nasal Spray 4 mg and prescription KLOXXADO® Nasal Spray 8 mg.

Emergent BioSolutions (NYSE:EBS) reported Q2 2025 financial results with total revenues of $140.9 million, exceeding guidance by $21 million. The company posted a net loss of $12.0 million, a 96% improvement from the previous year. Key metrics include a gross margin of 36% and adjusted EBITDA of $28.5 million, representing a 382% increase year-over-year.

Notable achievements include securing seven biodefense contract modifications and a $65 million multi-year contract with Ontario Ministry of Health for NARCAN® Nasal Spray. The company's product portfolio performance showed mixed results, with Naloxone revenues decreasing 44% to $67.5 million, while Smallpox MCM products increased 127% to $40.6 million.

Management has raised the low end/midpoint of full year 2025 profitability guidance, citing strong execution of their multi-year transformation plan and sustained demand for naloxone products.

Emergent BioSolutions (NYSE: EBS) commends the U.S. House of Representatives for implementing over-the-counter (OTC) naloxone availability at all AED locations in its buildings. The initiative, led by Representative Buddy Carter (R-GA), aims to provide immediate access to life-saving treatment for potential opioid overdoses.

The company highlights that its NARCAN® Nasal Spray, the first OTC opioid overdose reversal treatment, has contributed to reducing overdose deaths according to CDC data. Since 2016, over 85 million doses have been distributed across the U.S. and Canada. As the leading U.S. supplier of nasal naloxone, Emergent offers multiple products including NARCAN® 4mg, KLOXXADO® 8mg, and various convenience kits.

Emergent BioSolutions (NYSE:EBS) announced the publication of a review article in Expert Review of Anti-infective Therapy evaluating brincidofovir as a potential treatment for mpox. The article examines brincidofovir's in vitro and in vivo data, human case studies, and its current evaluation in the Democratic Republic of Congo.

The publication comes amid ongoing global mpox outbreaks, with the WHO declaring a Public Health Emergency of International Concern (PHEIC) on August 14, 2024. Brincidofovir is being evaluated in the MpOx Study in Africa (MOSA), a double-blind, placebo-controlled clinical trial that began in January 2025, conducted in partnership with PANTHER and funded by Horizon Europe and Africa CDC.

Emergent BioSolutions (NYSE:EBS) has scheduled its second quarter 2025 financial results conference call for August 6, 2025, at 5:00 PM ET. The company will provide access to the call through multiple channels, including a live webcast available on their Investors webpage.

Telephone participants must pre-register through a provided link to receive dial-in information and unique access credentials. A replay of the conference call will be made available on the company's Investors page after the event.

Emergent BioSolutions (NYSE:EBS) has secured a significant $51.9 million contract modification from the Administration for Strategic Preparedness and Response (ASPR) for its CNJ-016® (VIGIV) treatment. The contract is part of the U.S. government's smallpox preparedness strategy, extending an existing 10-year agreement for additional doses of VIGIV, which treats complications from smallpox vaccination.

The announcement follows Emergent's recent BAT® (Botulism Antitoxin Heptavalent) contract amendment with ASPR. VIGIV is a 5% Liquid Immune Globulin treatment indicated for various vaccinia vaccination complications, including eczema vaccinatum and progressive vaccinia, though not for postvaccinial encephalitis.

Emergent BioSolutions (NYSE:EBS) has expanded its NARCANDirect® online distribution network to include KLOXXADO® (naloxone HCl) Nasal Spray 8 mg, complementing its existing NARCAN® 4 mg nasal spray offering. The expansion, effective July 1, 2025, follows Emergent's acquisition of KLOXXADO's exclusive commercial rights in the U.S. and Canada in January 2025.

The platform serves qualified direct purchasers including emergency services, law enforcement, schools, and community-based programs. The company is also introducing Convenience Kits featuring CPR masks and nitrile gloves. This expansion comes as CDC data shows a 27% decrease in drug overdose deaths in 2024, though recent data indicates a slight uptick of 1,400 deaths between January 2024 and January 2025.

Emergent BioSolutions (NYSE: EBS) has secured a $62.4 million contract modification from the Administration for Strategic Preparedness and Response (ASPR) for their BAT® (Botulism Antitoxin Heptavalent) product. This modification extends their existing 10-year contract with ASPR for supplying BAT®, a treatment for symptomatic botulism exposure to neurotoxin serotypes A through G in both adults and children. The contract reinforces the U.S. government's commitment to maintaining critical medical countermeasures in its biodefense stockpile. Emergent BioSolutions will leverage its North American supply chain to deliver this life-saving solution, contributing to public health protection and global emergency preparedness.